{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:15:04Z","timestamp":1789985704972,"version":"4.0.1"},"reference-count":49,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T00:00:00Z","timestamp":1519084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Respir Care"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:p>Antibiotics have previously demonstrated anti-inflammatory properties, and they have been linked to therapeutic benefit in several pulmonary conditions that feature inflammation. Previous research suggests that these anti-inflammatory properties may be beneficial in the treatment of COPD. This review assesses the potential benefit of prophylactic, long-term, and low-dose antibiotic therapy in COPD, and whether any effects seen are anti-inflammatory in nature. Randomized, controlled trials comparing antibiotic therapy with placebo in subjects with stable COPD were evaluated. Twelve trials involving 3,784 participants and a range of antibiotics were included: azithromycin (6 studies, 1,972 participants), clarithromycin (1 study, 67 participants), erythromycin (3 studies, 254 participants), roxithromycin (1 study, 191 participants), and moxifloxacin (2 studies, 1,198 participants). In vitro, in vivo, and ex vivo experimental study designs exploring the mechanisms via which antibiotics may act in subjects with stable COPD were evaluated. Azithromycin and erythromycin showed the greatest effect in subjects with COPD, with evidence suggesting improvement in exacerbation-related outcomes and health status, as measured by the St George Respiratory Questionnaire. An increase in antibiotic resistance was reported in 2 studies. The macrolide class of antibiotics exhibited convincing anti-inflammatory properties with relevance to COPD, implicating several pathways as potential mechanisms of action. In conclusion, the therapeutic benefit of macrolide antibiotics in subjects with stable COPD is consistent with anti-inflammatory properties, and macrolides should be considered as a potential therapy in COPD. Safety concerns regarding antibiotic resistance need to be addressed before widespread use in clinical practice.<\/jats:p>","DOI":"10.4187\/respcare.05943","type":"journal-article","created":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T20:20:13Z","timestamp":1519158013000},"page":"609-619","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":50,"title":["Prophylactic Antibiotic Use in COPD and the Potential Anti-Inflammatory Activities of Antibiotics"],"prefix":"10.1177","volume":"63","author":[{"given":"Anthony W","family":"Huckle","sequence":"first","affiliation":[{"name":"School of Life Sciences, University of Nottingham, Nottingham, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy C","family":"Fairclough","sequence":"additional","affiliation":[{"name":"School of Life Sciences, University of Nottingham, Nottingham, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Todd","sequence":"additional","affiliation":[{"name":"School of Life Sciences, University of Nottingham, Nottingham, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,2,20]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"Global Strategy for the Diagnosis Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. http:\/\/goldcopd.org. Accessed on 8 Dec 2017."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2012-0492TR"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1042\/CS20110062"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2005.00947.x"},{"key":"e_1_3_3_6_2","first-page":"254","article-title":"Clinical effect of low-dose long-term administration of macrolides on diffuse panbronchiolitis","volume":"22","author":"Kudoh S","year":"1984","unstructured":"Kudoh S, , Kimura H. Clinical effect of low-dose long-term administration of macrolides on diffuse panbronchiolitis. Japan J Thorac Dis, 1984; 22(Suppl.):254.","journal-title":"Japan J Thorac Dis"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.6.9710075"},{"key":"e_1_3_3_8_2","first-page":"CD009764","article-title":"Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)","volume":"11","author":"Herath SC","year":"2013","unstructured":"Herath SC, , Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev, 2013; 11:CD009764.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104623"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-14-125"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207194"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105609"},{"key":"e_1_3_3_13_2","first-page":"A5580","article-title":"A randomised, placebo-controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease","volume":"36","author":"Mygind L","year":"2010","unstructured":"Mygind L, , Torp-Pedersen C, , Vestbo J, , Christensen JJ, , Frimodt-M\u00f8ller N, , Kirstiansen IS. A randomised, placebo-controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. Eur Respir J, 2010; 36:A5580.","journal-title":"Eur Respir J"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(14)70019-0"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00151829-200403010-00007"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000321374"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200801-145OC"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.120.3.730"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12952-015-0034-8"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-11-10"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-10-4"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032158"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041892"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2014.09.006"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00063198-199803000-00010"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1159\/000320319"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2011.04.004"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2006.01.079"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-10-89"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2010.12.013"},{"key":"e_1_3_3_31_2","first-page":"179","article-title":"Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial","volume":"9","author":"Siva R","year":"2014","unstructured":"Siva R, , Bafadhel M, , Monteiro W, , Brightling CE, , Pavord ID. Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis, 2014; 9:179\u2013186.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2015.10.009"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00001506"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200711-1666OC"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2009.12.002"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2011.02.001"},{"key":"e_1_3_3_37_2","first-page":"A5585","article-title":"Anti-inflammatory effects of azithromycin evaluated by in vivo imaging of NF-KB activation in a mouse model of acute lung inflammation","volume":"185","author":"Stellari FF","year":"2012","unstructured":"Stellari FF, , Caruso P, , Topini T, , Carnini C, , Facchinetti F, , Villetti G. Anti-inflammatory effects of azithromycin evaluated by in vivo imaging of NF-KB activation in a mouse model of acute lung inflammation. Am J Respir Crit Care Med, 2012; 185:A5585.","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_3_3_38_2","article-title":"Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung","author":"Segal LN","year":"2016","unstructured":"Segal LN, , Clemente JC, , Wu BG, , Wikoff WR, , Gao Z, , Li Y, et al. Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung. Thorax, 2016.","journal-title":"Thorax"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200806-905OC"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2011.12.022"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4173962"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.200733"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12574"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.115.3.829"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.2165\/00151829-200504030-00003"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.51.3.267"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00241.2005"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.10.2375"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.8.2450-2457.2003"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.27.1.42"}],"container-title":["Respiratory Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.4187\/respcare.05943","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4187\/respcare.05943","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4187\/respcare.05943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T11:08:33Z","timestamp":1775473713000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.4187\/respcare.05943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,20]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.4187\/respcare.05943"],"URL":"https:\/\/doi.org\/10.4187\/respcare.05943","relation":{},"ISSN":["0020-1324"],"issn-type":[{"value":"0020-1324","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2,20]]}}}